Physician profile
Blanca E Pyle
NPI 1952426611
$6,768.70
in general payments reported to CMS, 2019-2025
45 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $1,718 · 2023: $1,013 · 2024: $1,719 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,283.56 | 2022 | |
| Abbvie INC. | $819.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $638.33 | 2021-2025 | Airsupra, Nexium, Breztri |
| Supernus Pharmaceuticals, INC. | $510.03 | 2023-2024 | Qelbree, Qelbree |
| Amgen INC. | $344.48 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $291.19 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $290.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $220.98 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $211.57 | 2024-2025 | Biktarvy |
| Esperion Therapeutics, INC. | $186.61 | 2021-2025 | Nexletol |
| Pfizer INC. | $179.69 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $178.64 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.19 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $146.51 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $142.35 | 2023-2025 | Xarelto, Spravato |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $101.32 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $78.97 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $74.56 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Exact Sciences Corporation | $64.61 | 2024-2025 | Cologuard Collection Kit |
| Corium, LLC | $62.16 | 2023-2024 | Azstarys |
| Abbott Laboratories | $62.12 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $57.36 | 2025 | Gemtesa |
| Abiomed | $44.84 | 2025 | |
| Astellas Pharma US INC | $44.79 | 2022-2025 | Veozah |
| Axsome Therapeutics, INC. | $44.29 | 2025 | Symbravo |
| Lundbeck LLC | $43.08 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $42.02 | 2024 | Unithroid |
| Viiv Healthcare Company | $39.66 | 2025 | Apretude |
| Electromed, INC. | $38.70 | 2024 | Smartvest |
| Genentech USA, INC. | $38.21 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.30 | 2021-2025 | Xifaxan |
| Dexcom, INC. | $29.96 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $29.07 | 2025 | Minimed 780g |
| Seqirus USA INC | $23.42 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Vertical Pharmaceuticals, LLC | $23.09 | 2024 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.72 | 2023 | |
| Boston Scientific Corporation | $22.01 | 2024 | |
| Impel Pharmaceuticals INC. | $21.61 | 2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $20.34 | 2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $19.84 | 2024 | Voquezna |
| Corcept Therapeutics | $17.69 | 2025 | Korlym |
| Noven Therapeutics, LLC | $17.57 | 2024 | Xelstrym |
| Horizon Therapeutics Plc | $17.43 | 2021 | |
| Organon LLC | $16.78 | 2023 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blanca Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.